Oral glucocorticoids vs. intravenous glucocorticoids in managing thyroid associated orbitopathy

Not Applicable

• Conditions: Health Condition 1: null- Patients of Gravesâ?? disease with eye symptoms suggestive of Thyroid associated orbitopathy

• Registration Number: CTRI/2013/12/004264
• Lead Sponsor: Department of Endocrinology and Metabolism

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

Patients of moderately severe Thyroid associated orbitopathy (TAO) with moderate activity (Clinical activity score >2)were included.

Moderate to severe TAO was defined as marked soft tissue swelling (2c by NOSPECS), and/or proptosis (>=18mm in females; >=20mm in males; 3a or more by NOSPECS), and/or inconstant/constant diplopia in primary or reading position (4b by NOSPECS), and/or punctuate staining of cornea, without any optic nerve involvement, as suggested by European Group on Gravesâ?? Orbitopathy

Exclusion Criteria

Patients with mild TAO, dysthyroid optic neuropathy (DON) and severe sight-threatening TAO were excluded.Patients were excluded who had received steroids, radiotherapy, immunosuppressive therapy or surgery for TAO. Patients with comorbidities making glucocorticoid administration difficult (uncontrolled hypertension, uncontrolled diabetes, tuberculosis, immune-compromised state, chronic liver disease, viral hepatitis, tuberculosis) were excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified